Antengene's Breakthrough Therapy Designation for ATG-022 Marks a New Era in Gastric Cancer Treatment Antengene's ATG-022 has received Breakthrough Therapy designation for treating gastric and gastroesophageal junction cancers, offering new hope for patients.

Antengene's Breakthrough Therapy Designation for ATG-022 Marks a New Era in Gastric Cancer Treatment #China #Shanghai #Antengene #ATG-022 #Breakthrough_Therapy